Form4insider filings, from the source

SEC Form 4 · accession 0001193805-15-001013

ANTARES PHARMA, INC. · ATRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
DEERFIELD MANAGEMENT CO
10% Owner · Other
Deerfield Mgmt L.P.
10% Owner · Other
DEERFIELD PARTNERS, LP
10% Owner · Other
James E Flynn
10% Owner · Other
Period of report
Jun 16, 2015
Accepted (ET)
Jun 18, 2015 · 5:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Jun 16, 2015S15,175$2.4035D3,775,126IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 16, 2015S45,710$2.4035D9,496,683IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 16, 2015S35,915$2.4035D7,461,679IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 16, 2015S18,382$2.4021D3,756,744IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 16, 2015S55,372$2.4021D9,441,311IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 16, 2015S43,506$2.4021D7,418,173IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 17, 2015S8,403$2.4053D3,748,341IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 17, 2015S25,313$2.4053D9,415,998IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 17, 2015S19,889$2.4053D7,398,284IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 18, 2015S32,419$2.4756D3,715,922IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 18, 2015S97,654$2.4756D9,318,344IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 18, 2015S76,728$2.4756D7,321,556IThrough Deerfield Partners, L.P.
Common StockF1,F2Jun 18, 2015S611$2.48D3,715,311IThrough Deerfield Special Situations Fund, L.P.
Common StockF1,F2Jun 18, 2015S1,842$2.48D9,316,502IThrough Deerfield International Master Fund, L.P.
Common StockF1,F2Jun 18, 2015S1,447$2.48D7,320,109IThrough Deerfield Partners, L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Avalanche Biotechnologies, Inc. filed with the Securities and Exchange Commission on July 30, 2014 by Deerfield Mgmt III, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., Deerfield Special Situations International Master Fund, L.P., Deerfield Private Design Fund III, L.P. and James E. Flynn.